MedroxyTM is indicated for:
1. Ovulation suppression
2. The treatment of endometriosis.
3. Adjunctive and/or pallivative treatment of recurrent and/or metastatic endometrial or renal carcinoma.
4. The treatment of hormonally-dependant recurrent breast cancer in post-menopausal women.
Dosage & Administration
MedroxyTM injectables suspension should be vigorously shaken just before use to ensure that the dose being administered represents a uniform suspension. The recommended dose is 150mg of MedroxyTM injectable suspension every three months administered by intramuscular injection in the gluteal or deltoid muscle. The initial injection should be given during the first 5 days after the onset of a menstrual period; within the 5 days post partum if not breast feeding; of if exclusively breast-feeding at or after six weeks post-partum.
Based on limited experience, some investigators favour the use of a second injection of MedroxyTM before 90 days to control troublesome bleeding. The third and subsequent injections should be administered at separate 90 days intervals.
If abnormal bleeding persists, appropriate investigations should be instituted to rule out the possibility of organic pathology. Uterine curettage may be required on rare occations.
50mg weekly intramuscularly or 100mg every 2 weeks intramuscularly for at least 6 months.
Endometrial and Renal Carcinoma
Doses of 500mg to 1000mg of intramuscularly per week are recommended initially. It may be possible to maintain improvement with 500mg per week or less. MedroxyTM is not recommended as primarily therapy, but as adjunctive & palliative treatment in advanced inoperable cases including those with recurrent or metastatic disease.
500mg to 1000mg per day intramuscularly for 28 days. Maintenance dose is 500mg twice weekly as long as she is responding to treatment. Response to hormonal therapy (MedroxyTM ) for breast cancer may not be evident until 8-10 weeks of therapy. Treatment with MedroxyTM should be terminated if rapid progression of disease occurs at any time during therapy.
Unexpected vaginal bleeding during therapy, patient with a preexisting medical condition that might be adversely affected by fluid retention, patients with a history of treatment for clinical depression diabetic patient. It may decrees the level of the following endocrine biomarkers: Plasma /urinary steroid (eg: cortisol, oestrogen, pregnanediol , progesterone & testosterone ) Plasma /urinary gonadotrophin (eg: LH & FSH) & sex -hormonebinding- globulin (SHBG)
Pregnancy And Lactation